8-Chloroadenosine induced HL-60 cell growth inhibition, differentiation, and G0/G1 arrest involves attenuated cyclin D1 and telomerase and up-regulated p21WAF1/CIP1

Journal of Cellular Biochemistry

Volumn 97, Issue 1, 2006, Pages 166-177

  Zhu, Bing ^a   Zhang, Li He ^b   Zhao, Yong Mei ^a   Cui, Jing Rong ^b   Strada, Samuel J ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

8 chloroadenosine; Cyclin D1; Differentiation; HL 60; p21WAF1 CIP1; Telomerase

Indexed keywords

8 CHLOROADENOSINE; 8 CHLOROADENOSINE 3',5' PHOSPHATE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL LINEAGE; CELL STRAIN HL 60; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; GRANULOCYTE; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

2-CHLOROADENOSINE; APOPTOSIS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL DIVISION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; G0 PHASE; G1 PHASE; HL-60 CELLS; HUMANS; TELOMERASE;

EID: 30044436068     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20630     Document Type: Article

References (61)

1. Akiyama N, Sasaki H, Katoh O, Sato T, Hirai H, Yazaki Y, Sugimura T, Terada M. 1993. Increment of the cyclin D1 mRNA level in TPA-treated three human myeloid leukemia cell linespHEL, CMK, and HL-60 cells. Biochem Biophys Res Commun 195:1041-1049.
2. Alexandrow MG, Moses HL. 1995. Transforming growth factor β and cell-cycle regulation. Cancer Res 55:1452-1457.
3. Ally S, Clair T, Katsaros D, Tortora G, Yokozaki H, Finch RA, Avery TL, Cho-Chung YS. 1989. Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cAMP. Cancer Res 49:5650-5655.
4. Bestilny LJ, Brown CB, Miura Y, Robertson LD, Riabowol KT. 1996. Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res 56:3796-3802.
5. Burger C, Wick M, Muller R. 1994. Lineage-specific regulation of cell-cycle gene expression in differentiating myeloid cells. J Cell Sci 107:2047-2054.
6. Carlson CC, Chinery R, Burnham LL, Dransfield DT. 2000. 8-Cl-adenosine-induced inhibition of colorectal cancer growth in vitro and in vivo. Neoplasia 2:441-448.
7. Cummings J, Leonard RC, Miller WR. 1994. Sensitive determination of 8-chloroadenosine 3′,5′-monophosphate and 8-chloroadenosine in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 658:183-188.
8. Cummings J, Langdon SP, Ritchie AA, Burns DJ, Mackay J, Stockman P, Leonard RC, Miller WR. 1996. Pharmacokinetics, metabolism, and tumour disposition of 8-chloroadenosine 3′,5′-monophosphate in breast cancer patients and xenograft bearing mice. Ann Oncol 7:291-296.
9. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang X. 1995. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92:5545-5549.
10. WAF1/CIP1/MDA6expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60). Leukemia 11:504-513.
11. Gandhi V, Ayres M, Halgren RG, Krett NL, Newman RA, Rosen ST. 2001. 8-Chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res 61:5474-5479.
12. Gartel AL, Serfas MS, Tyner AL. 1996. p21-negative regulator of the cell cycle. Pro Soc Exp Biol Med 213: 138-149.
13. Halgren RG, Traynor AE, Pillay S, Zell JL, Heller KF, Krett NL, Rosen ST. 1998. 8Cl-cAMP cytotoxicity in both steroid sensitive and insensitive multiple myeloma cell lines is mediated by 8Cl-adenosine. Blood 92:2893-2898.
14. Harada K, Kurisu K, Sadatomo T, Tahara H, Tahara E, Ide T, Tahara E. 2000. Growth inhibition of human glioma cells by transfection-induced p21 and its effects on telomerase activity. J Neuro-Oncol 47:39-46.
15. Hass R, Gunji H, Datta R, Kharbanda S, Hartmann A, Weichselbaum R, Kufe D. 1992. Differentiation and retrodifferentiation of human myeloid leukemia cells is associated with reversible induction of cell-cycle regulatory genes. Cancer Res 52:1445-1450.
16. Henderson YC, Breau RL, Liu TJ, Clayman GL. 2000. Telomerase activity in head and neck tumors after introduction of wild-type p53, p21, p16, and E2F-1 genes by means of recombinant adenovirus. Head Neck 22: 347-354.
17. Hirano T, Gotoh M, Oka K. 1994. Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci 55:1061-1069.
18. Horiguchi-Yamada J, Yamada H. 1993. Differing responses of G2-related genes during differentiation of HL60 cells induced by TPA and DMSO. Mol Cell Biochem 119:29-34.
19. Horiguchi-Yamada J, Yamada H, Nakada S, Ochi K, Nemoto T. 1994. Changes of G1 cyclins, cdk2, and cyclin A during the differentiation of HL60 cells induced by TPA. Mol Cell Biochem 132:31-37.
20. Janknecht R. 2004. On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett 564:9-13.
21. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. 1994. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9:3397-3406.
22. Kagawa S, Fujiwara T, Kadowaki Y, Fukazawa T, Sok-Joo R, Roth JA, Tanaka N. 1999. Overexpression of the p21 sdi 1 gene induces senescence-like state in human cancer cells: Implication for senescence-directed molecular for cancer. Cell Death Differ 6:765-772.
23. Lamb D, Steinberg RA. 2002. Anti-proliferative effects of 8-chloro-cAMP and other cAMP analogs are unrelated to their effects on protein kinase A regulatory subunit expression. J Cell Physiol 192:216-224.
24. Langdon SP, Ritchie AA, Muir M, Dodds M, Howie AF, Leonard RC, Stcokman PK, Miller WR. 1998. Antitumour activity and schedule dependency of 8-chloroadenosine-3′,5′-monophosphate (8-ClcAMP) against human tumor xenografts. Eur J Cancer 34:384-388.
25. Langeveld CH, Jongenelen CA, Heimans JJ, Stoof JC. 1992. Growth inhibition of human glioma cells induced by 8-chloroadenosine, an active metabolite of 8-chloro cyclic adenosine 3′,5′-monophosphate. Cancer Res 52: 3994-3999.
26. Langeveld CH, Jongenelen CA, Theeuwes JW, Baak JP, Heimans JJ, Stoof JC, Peters GJ. 1997. The antiproliferative effect of 8-chloro-adenosine: An active metabolite of 8-chloro-cyclic adenosine monophosphate, and disturbances in nucleic acid synthesis and cell-cycle kinetics. Biochem Pharmacol 53:141-148.
27. Li ZR, Hromchak R, Mudipalli A, Bloch A. 1998. Tumor suppressor proteins as regulators of cell differentiation. Cancer Res 58:4282-4287.
28. Kip1 mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem 272:7093-7098.
29. Missailidis S, Stanslas J, Modi C, Ellis MJ, Robins RA, Laughton CA, Stevens MF. 2002. Antitumor polycyclic acridines. Part 12. Physical and biological properties of 8,13-diethyl-6-methylquino[4,3,2-k1]acridinium iodide: A lead compound in anticancer drug design. Oncol Res 13:175-189.
30. Newberger P, Chovaniee M, Greenberger J, Cohen H. 1979. Functional changes in human leukemic cell line HL-60: A model for myeloid differentiation. J Cell Biol 82:315-322.
31. Newbold RF. 2002. The significance of telomerase activation and cellular immortalization in human cancer. Mutagenesis 17:539-550.
32. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279.
33. Noguchi K, Murata T, Cho-Chung YS. 1998. 8-Chloroadenosine 3′,5′-monophosphate (8-Cl-cAMP) selectively eliminates protein kinase A type I to induce growth inhibition in c-ras-transformed fibroblasts. Eur J Cancer 34:1260-1267.
34. Park GH, Choe J, Choo HJ, Park YG, Sohn J, Kim MK. 2002. Genome-wide expression profiling of 8-chloroadenosine-and 8-chloro-cAMP-treated human neuroblastoma cells using radioactive human cDNA microarray. Exp Mol Med 34:184-193.
35. 6-benzyl-cyclic adenosine 5′-monophosphate on cell-cycle kinetics of HL-60 leukemia cells. Cancer Res 51:6263-6267.
36. Philipp A, Schneider A, Vasrik I, Finke K, Xiong Y, Beach D, Alitalo K, Eliers M. 1994. Repression of cyclin D1: A novel function of MYC. Mol Cell Biol 14:4032-4043.
37. KIP1: A cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell-cycle arrest. Genes Dev 8:9-22.
38. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL. 1997. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272:10882-10894.
39. CIP1/WAF1 induction rather than AKT inhibition. Oncogene 22:6231-6242.
40. Rama S, Suresh Y, Rao AJ. 2001. Regulation of telomerase during human placental differentiation: A role for TGF β1. Mol Cell Endocrinol 182:233-248.
41. Rama S, Suresh Y, Rao AJ. 2003. TGF β1 induces multiple independent signals to regulate human trophoblastic differentiation: Mechanistic insights. Mol Cell Endocrinol 206:123-136.
42. Ramage AD, Langdon SP, Ritchie AA, Burns DJ, Miller WR. 1995. Growth inhibition by 8-chloro-cyclic AMP of human HT29 colorectal and ZR-75-1 breast carcinoma xenografts is associated with selective modulation of protein kinase A isozymes. Eur J Cancer 31A: 969-973.
43. Reichman TW, Albanell J, Wang X, Moore MAS, Studzinski GP. 1997. Downregulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated protein. J Cell Biochem 67:13-23.
44. Robbins SK, Houlbrook S, Priddle JD, Harris AL. 2001. 8-Cl-adenosine is an active metabolite of 8-Cl-cAMP responsible for its in vitro antiproliferative effects on CHO mutants hypersensitive to cytostatic drugs. Cancer Chemother Pharmacol 48:451-458.
45. Rohlff C, Clair T, Cho-Chung YS. 1993. 8-Cl-cAMP induces down-regulation of the RIα subunit and up-regulation of the RIIβ subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J Biol Chem 268:5774-5782.
46. WAF1/CIP1/SDI1 in differentiating human leukemic cells. J Clin Invest 95:973-979.
47. INK4D) in human acute myeloid leukemia and normal myeloid cells. Leukemia 11:54-63.
48. Silberstein GB, Daniel CW. 1987. Reversible inhibition of mammary gland growth by transforming growth factor-β. Science 237:291-293.
49. Tauchi T, Shin-Ya K, Sashida G, Sumi M, Nakajima A, Shimamoto T, Ohyashiki JH, Ohyashiki K. 2003. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: Involvement of ATM-dependent DNA damage response pathways. Oncogene 22:5338-5347.
50. Thompson WJ, Ashikaga T, Kelly JJ, Liu L, Zhu B, Vemavarapu L, Strada SJ. 2002. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). Biochem Pharmacol 63:797-807.
51. Tortora G, Clair T, Katsaros D, Ally S, Colamonici O, Neckers LM, Tagliaferri P, Jahnsen T, Robins RK, Cho-Chung YS. 1989. Induction of megakaryocytic differentiation and modulation of protein kinase gene expression by site-selective cAMP analogs in K-562 human leukemic cells. Proc Natl Acad Sci USA 86:2849-2852.
52. Tortora G, Ciardiello F, Pepe S, Tagliaferri P, Ruggiero A, Bianco C, Guarrasi R, Miki K, Bianco AR. 1995. Phase I clinical study with 8-chloro-cAMP and evaluation of immunologic effects in cancer patients. Clin Cancer Res 1:377-384.
53. Tortora G, di Isernia G, Sandomenico C, Bianco R, Pomatico G, Pepe S, Bianco AR, Ciardiello F. 1997. Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res 57:5107-5111.
54. Wang X, Studzinski GP. 1997. Antispoptotic action of 1,25- dihydroxyvitamin D3 is associated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced release of cytochrome c. Exp Cell Res 235:210-217.
55. 1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 56:264-267.
56. Kip1 levels by its antisense or by development of resistance to 1,25-dihydroxyvitamin D3 reverses the G1 block but not differentiation of HL60 cells. Leukemia 12:1256-1265.
57. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
58. Yin Y, Allen PD, Jia L, Kelsey SM, Newland AC. 2001. 8-Cl-adenosine mediated cytotoxicity and sensitization of T-lymphoblastic leukemia cells to TNFa-induced apoptosis is via inactivation of NF-κB. Leuk Res 25:423-431.
59. Zeng XL, Tu ZG. 2003. In vitro induction of differentiation by ginsenoside Rh2 in SMMC-7721 hepatocarcinoma cell line. Pharmacol Toxicol 93:275-283.
60. 0 phase cell-cycle block. Cell Proliferation 27:643-654.
61. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. 2005. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 94:336-350.